The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of omalizumab for treating chronic rhinosinusitis with nasal polyps.
Following discussions with the company the timelines for this appraisal are currently to be confirmed.
NICE will continue to monitor the situation and provide an update as and when the situation changes.